Plasma Levels of Advanced Glycation Endproducts N∈-(carboxymethyl)lysine, N∈-(carboxyethyl)lysine, and Pentosidine Are not Independently Associated With Cardiovascular Disease in Individuals With or Without Type 2 Diabetes: The Hoorn and CODAM Studies
Plasma Levels of Advanced Glycation Endproducts N∈-(carboxymethyl)lysine, N∈-(carboxyethyl)lysine, and Pentosidine Are not Independently Associated With Cardiovascular Disease in Individuals With or Without Type 2 Diabetes: The Hoorn and CODAM Studies
复制标题
DOI：
10.1210/jc.2013-1068
复制
发表时间：
2013-08-01
影响因子：
5.8
通讯作者：
Schalkwijk, Casper G.
中科院分区：
文献类型：
--
作者：
Hanssen, Nordin M. J.;Engelen, Lian;Schalkwijk, Casper G.
目的：实验和组织学数据表明，晚期糖基化终产物（AGEs）在心血管疾病（CVD），特别是2型糖尿病（T2 DM）中的作用。然而，AGEs和CVD之间不良关联的流行病学证据仍然不确定。因此，我们调查了不同程度的葡萄糖代谢的个体，血浆AGEs与流行的CVD的关联。研究设计和方法：我们测量了血浆中蛋白质结合N-的水平，N-是一种元素，（羧甲基）赖氨酸（CML），N-是-（羧乙基）赖氨酸（CEL）和戊糖苷，来自两项荷兰队列研究的参与者（n = 1291，平均年龄64.7 ± 8.3岁，45%为女性），包括573名糖代谢正常的个体，304名糖代谢受损的个体和414名T2 DM患者。此外，我们还测量了一部分参与者（n = 554）的游离CML、CEL和5-氢-5-甲基咪唑酮。资料采用多元Logistic回归或线性回归分析。（32 [四分位距：2540 vs 28 [22-35] nmol/mmol赖氨酸]）和戊糖苷（0.53 [0.43-0.67] vs 0.48 [0.40-0.59] nmol/mmol赖氨酸）以及游离CEL（48 [39-62] vs 45 [36-56] nmol/L）和5-氢-5-甲基咪唑酮（141 [96-209] vs 116 [84-165] nmol/L）在患有心血管疾病的个体中高于无心血管疾病的个体，而蛋白结合的CML较低（33 [27-38] vs 34 [29-39] nmol/mmol赖氨酸）。然而，这些差异在调整混杂因素后消失。结论：在糖代谢正常、糖代谢受损和T2 DM患者中，血浆AGEs与CVD之间无独立的不良相关性。
Objective: Experimental and histological data suggest a role for advanced glycation end products (AGEs) in cardiovascular disease (CVD), particularly in type 2 diabetes (T2DM). However, the epidemiological evidence of an adverse association between AGEs and CVD remains inconclusive. We therefore investigated, in individuals with various degrees of glucose metabolism, the associations of plasma AGEs with prevalent CVD.Research Design and Methods: We measured plasma levels of protein-bound N-is an element of-(carboxymethyl)lysine (CML), N-is an element of-(carboxyethyl)lysine (CEL), and pentosidine, in participants from two Dutch cohort studies (n = 1291, mean age 64.7 +/- 8.3 years, 45% women), including 573 individuals with normal glucose metabolism, 304 with impaired glucose metabolism, and 414 with T2DM. In addition, we measured free CML, CEL, and 5-hydro-5-methylimidazolone in a subset of participants (n = 554). Data were analyzed with multiple logistic or linear regression analyses.Results: CEL (32 [interquartile range: 2540 vs 28 [22-35] nmol/mmol lysine]) and pentosidine (0.53 [0.43-0.67] vs 0.48 [0.40-0.59] nmol/mmol lysine) as well as free CEL (48 [39-62] vs 45 [36-56] nmol/L) and 5-hydro-5-methylimidazolone (141 [96-209] vs 116 [84-165] nmol/L) were higher in individuals with vs without CVD, whereas protein-bound CML was lower (33 [27-38] vs 34 [29-39] nmol/mmol lysine). However, these differences disappeared after adjustment for confounders. The associations did not differ consistently between individuals with and without T2DM.Conclusions: We found no independent adverse associations of plasma AGEs with CVD in individuals with normal glucose metabolism, impaired glucose metabolism, and T2DM.